Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer

BACKGROUND: The efficacy of bevacizumab in non-small cell lung cancer (NSCLC) patients is unsatisfactory, and the selection of suitable patients is still challenging. Given the epigenetic modifications can contribute to an aberrant regulation of angiogenesis and microenvironment, we investigated DNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Butuo, Jiang, Chao, Xu, Yiyue, Fan, Xinyu, Yang, Linlin, Zou, Bing, Fan, Bingjie, Wang, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338664/
https://www.ncbi.nlm.nih.gov/pubmed/35906610
http://dx.doi.org/10.1186/s12885-022-09918-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338664/
https://www.ncbi.nlm.nih.gov/pubmed/35906610
http://dx.doi.org/10.1186/s12885-022-09918-1

Ejemplares similares